SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Jeff Collins to sit on the review panel for the Life Science Company Showcase Event at the North Carolina Biotechnology Center in Research Triangle Park, NC
News | 10. 15. 2008
